Schiff Hardin LLP is pleased to announce that four of the firm’s practice groups have been recognized in The Legal 500 United States 2021 guide, which provides a nationwide analysis of law firms that provide cutting-edge and innovative advice.
President Biden recently announced his support for easing patent rules surrounding COVID-19 vaccines and other COVID-related intellectual property in the wake of growing crises in India and South Africa.
Schiff Hardin LLP is pleased to announce that Intellectual Property Group Co-Leader Imron Aly has been named to Crain’s Chicago Business’ Notable Minorities in Accounting, Consulting & Law list for 2020.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel and partner Kevin Nelson were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2020 guide.
Schiff Hardin LLP is pleased to announce that the firm’s Intellectual Property Practice Group has received the Impact Case of the Year award in 2020 by LMG Life Sciences for our ground-breaking patent-infringement victory in Fresenius Kabi v. Hospira.
Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.
Schiff Hardin is pleased to announce that three Intellectual Property Practice Group attorneys have been recognized as IP Stars in Illinois for 2020 by Managing Intellectual Property.
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2019 guide.